These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 15942889

  • 1. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W.
    J Infect Dis; 2005 Jul 01; 192(1):16-23. PubMed ID: 15942889
    [Abstract] [Full Text] [Related]

  • 2. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T.
    J Infect Dis; 2005 Jul 01; 192(1):30-6. PubMed ID: 15942891
    [Abstract] [Full Text] [Related]

  • 3. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H, Vignoles M, Laufer N, Gómez A, Coll P, Lottner J, Rolón M, Salomón H, Cahn P.
    Antivir Ther; 2008 Jul 01; 13(1):135-9. PubMed ID: 18389908
    [Abstract] [Full Text] [Related]

  • 4. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa N, Leelawiwat W, Mock PA, Asavapiriyanont S, Teeraratkul A, McConnell MS, McNicholl JM, Tappero JW.
    Clin Infect Dis; 2009 Jul 15; 49(2):299-305. PubMed ID: 19522656
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, Preiser W.
    J Med Virol; 2008 Jun 15; 80(6):942-6. PubMed ID: 18428139
    [Abstract] [Full Text] [Related]

  • 7. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.
    Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL.
    J Infect Dis; 2002 Jul 15; 186(2):181-8. PubMed ID: 12134253
    [Abstract] [Full Text] [Related]

  • 8. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 9. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB.
    AIDS Res Hum Retroviruses; 2004 Jun 15; 20(6):595-9. PubMed ID: 15242535
    [Abstract] [Full Text] [Related]

  • 10. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    Flys T, Nissley DV, Claassen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.
    J Infect Dis; 2005 Jul 01; 192(1):24-9. PubMed ID: 15942890
    [Abstract] [Full Text] [Related]

  • 11. Nevirapine resistance after single dose prophylaxis.
    Eshleman SH, Jackson JB.
    AIDS Rev; 2002 Jul 01; 4(2):59-63. PubMed ID: 12152519
    [Abstract] [Full Text] [Related]

  • 12. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.
    AIDS; 2009 Apr 27; 23(7):825-33. PubMed ID: 19307941
    [Abstract] [Full Text] [Related]

  • 13. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Pilger D, Hauser A, Kuecherer C, Mugenyi K, Kabasinguzi R, Somogyi S, Harms G, Kunz A.
    Antivir Ther; 2011 Apr 27; 16(1):109-13. PubMed ID: 21311114
    [Abstract] [Full Text] [Related]

  • 14. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH.
    J Infect Dis; 2007 Mar 01; 195(5):711-5. PubMed ID: 17262714
    [Abstract] [Full Text] [Related]

  • 15. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB.
    J Infect Dis; 2001 Oct 01; 184(7):914-7. PubMed ID: 11509999
    [Abstract] [Full Text] [Related]

  • 16. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
    Schmitz T, Kleinkauf N, Klempa B, Ringe H, Varnholt V, Grosch-Wörner I.
    Pediatr Infect Dis J; 2006 Mar 01; 25(3):275-6. PubMed ID: 16511398
    [Abstract] [Full Text] [Related]

  • 17. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
    Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, Maldonado Y, Jones SA, Mofenson LM, Contag CH, Bassett M, Katzenstein DA, HIVNET 023 Study Team.
    J Infect Dis; 2005 Oct 01; 192(7):1260-4. PubMed ID: 16136470
    [Abstract] [Full Text] [Related]

  • 18. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.
    J Med Virol; 2015 Oct 01; 87(10):1662-7. PubMed ID: 25940687
    [Abstract] [Full Text] [Related]

  • 19. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Amani-Bosse C, Menan H, Leroy V, Rouzioux C, Dabis F.
    Antimicrob Agents Chemother; 2007 Mar 01; 51(3):896-901. PubMed ID: 17178792
    [Abstract] [Full Text] [Related]

  • 20. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS.
    AIDS Res Hum Retroviruses; 2007 May 01; 23(5):682-5. PubMed ID: 17530993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.